Unlocking translational proteomics for the
next stage of human health
Unlocking translational proteomics for the
next stage of human health
News
Developing Translational Proteomics For The Next Human Health Stage
Range Biotechnologies is a company developing translational proteomics (proteins) for the next stage of human health. Pulse 2.0 interviewed Range Biotechnologies co-founder and CEO Brandon Wilson, Ph.D., to learn more.
Developing Translational Proteomics For The Next Human Health Stage
Range Biotechnologies is a company developing translational proteomics (proteins) for the next stage of human health. Pulse 2.0 interviewed Range Biotechnologies co-founder and CEO Brandon Wilson, Ph.D., to learn more.
August 11, 2023
Powering precision medicine with proteomics
Longevity.Technology: Proteomics, the study of proteins in the body, has long been touted for its potential to help develop more effective ways to diagnose, treat and prevent diseases, but the field to date has largely focused on the discovery of protein biomarkers. Range Bio is founded on the belief that a significant impact on human health can only be realized if biomarker discovery is complemented by scalable, targeted quantification of proteins. We caught up with the company’s CEO Dr Brandon Wilson and CTO Dr Nicolo Maganzini to find out more.
Powering precision medicine with proteomics
Longevity.Technology: Proteomics, the study of proteins in the body, has long been touted for its potential to help develop more effective ways to diagnose, treat and prevent diseases, but the field to date has largely focused on the discovery of protein biomarkers. Range Bio is founded on the belief that a significant impact on human health can only be realized if biomarker discovery is complemented by scalable, targeted quantification of proteins. We caught up with the company’s CEO Dr Brandon Wilson and CTO Dr Nicolo Maganzini to find out more.
August 10, 2023
Seed Round Announcement
With the Potential to Revolutionize Personalized Health, Range Biotechnologies Receives $5.2 Million in Seed Funding Led by TechBio-Focused ARTIS Ventures. Range Bio seeks to enable better diagnostics and faster drug development by unlocking translational proteomics
Seed Round Announcement
With the Potential to Revolutionize Personalized Health, Range Biotechnologies Receives $5.2 Million in Seed Funding Led by TechBio-Focused ARTIS Ventures. Range Bio seeks to enable better diagnostics and faster drug development by unlocking translational proteomics
June 12, 2023
Let’s Chat
Strategic partners, investors, prospective employees: please reach out below for more information, or contact us at hello@range.bio